Current Pharmaceutical Biotechnology
Title: Preface
Volume: 1 Issue: 1
Author(s): Alain Rolland
Affiliation:
Export Options
About this article
Cite this article as:
Rolland Alain, Preface, Current Pharmaceutical Biotechnology 2000; 1 (1) . https://dx.doi.org/10.2174/1389201003378988
DOI https://dx.doi.org/10.2174/1389201003378988 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
10
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Survey of Resveratrol, Taxol, Podophyllotoxin, Withanolides and Their Derivatives Used in Anticancer Therapy
Recent Patents on Biotechnology Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Anticarcinogenic Effects of Capsaicin-Loaded Nanoparticles on In vitro Hepatocellular Carcinoma
Current Chemical Biology Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Current Pharmaceutical Biotechnology Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Multifactorial Regulation of GPER Expression in Cancer Cells and Cardiomyocytes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Nucleoside Phosphorylases
Current Organic Chemistry Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Membrane Domains and the “Lipid Raft” Concept
Current Medicinal Chemistry Established and Emerging Fluorescence-Based Assays for G-Protein Function: Ras-Superfamily GTPases
Combinatorial Chemistry & High Throughput Screening Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy